Gleave M - Search Results

1

SRRM4 gene expression correlates with neuroendocrine prostate cancer.

Li Y, Zhang Q, Lovnicki J, Chen R, Fazli L, Wang Y, Gleave M, Huang J, Dong X. Li Y, et al. Among authors: gleave m. Prostate. 2019 Jan;79(1):96-104. doi: 10.1002/pros.23715. Epub 2018 Aug 28. Prostate. 2019. PMID: 30155992

2

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

3

Differential transactivation by the androgen receptor in prostate cancer cells.

Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Snoek R, et al. Among authors: gleave m. Prostate. 1998 Sep 1;36(4):256-63. doi: 10.1002/(sici)1097-0045(19980901)36:4<256::aid-pros7>3.0.co;2-d. Prostate. 1998. PMID: 9719026

4

Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.

Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Leung SY, et al. Among authors: gleave me. Prostate. 2000 Jul 1;44(2):156-63. doi: 10.1002/1097-0045(20000701)44:2<156::aid-pros8>3.0.co;2-8. Prostate. 2000. PMID: 10881025

5

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.

Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Gleave ME, et al. Urology. 2001 Aug;58(2 Suppl 1):39-49. doi: 10.1016/s0090-4295(01)01241-9. Urology. 2001. PMID: 11502446

6

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.

July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. July LV, et al. Among authors: gleave me. Prostate. 2002 Feb 15;50(3):179-88. doi: 10.1002/pros.10047. Prostate. 2002. PMID: 11813210

7

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Gleave M, et al. Prostate Cancer Prostatic Dis. 1998 Dec;1(6):289-296. doi: 10.1038/sj.pcan.4500260. Prostate Cancer Prostatic Dis. 1998. PMID: 12496869

8

Application of gene microarrays in the study of prostate cancer.

Nelson CC, Hoffart D, Gleave ME, Rennie PS. Nelson CC, et al. Methods Mol Med. 2003;81:299-320. doi: 10.1385/1-59259-372-0:299. Methods Mol Med. 2003. PMID: 12725128 No abstract available.

9

Regulation of tumor angiogenesis by integrin-linked kinase (ILK).

Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S. Tan C, et al. Among authors: gleave m. Cancer Cell. 2004 Jan;5(1):79-90. doi: 10.1016/s1535-6108(03)00281-2. Cancer Cell. 2004. PMID: 14749128 Free article.

10

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. July LV, et al. Mol Cancer Ther. 2004 Mar;3(3):223-32. Mol Cancer Ther. 2004. PMID: 15026542

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

687 results

Search Page

Filters